Revolution Medicines reported that its KRAS(ON) inhibitor daraxonrasib hit prespecified endpoints in a pivotal Phase 3 trial in metastatic pancreatic ductal adenocarcinoma, extending survival versus standard chemotherapy and prompting the company to end the study early. The company said patients receiving daraxonrasib lived a median of 13.2 months compared with 6.7 months on chemotherapy, translating to a 60% reduction in the risk of death. Revolution indicated it plans to pursue rapid U.S. regulatory review after the FDA previously granted daraxonrasib a “national priority” voucher pilot slot. The company also signaled it will move toward filing and potential near-term approval discussions, as investors interpret the results as a meaningful step in a notoriously difficult disease setting. The readout further strengthens the broader push to target RAS-family biology in solid tumors, where earlier advances have started to change expectations for previously “undruggable” pathways. Analysts are likely to focus next on the trial’s requested regulatory package and how effects may vary by RAS(ON) biomarker status.